Ventriculopleural shunt outcomes for pediatric hydrocephalus: a single-institution experience

Oyon, Daniel E.; Behbahani, Mandana; Sharma, Shelly; Coons, Dana E; Pundy, Tatiana; Fernández, Luis G.; Gibson, William; Tomita, Tadanori

doi:10.1007/s00381-023-05928-x

Cited by 3 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shunt relocation includes VA shunt, VPL shunt, and LP shunt. 14 In our case, the patient developed an enlarging head circumference due to congenital hydrocephalus at 1 month of age. The etiology identified was aqueductal stenosis which was managed with a VP shunt.…”

Section: Discussionmentioning

confidence: 57%

“…Surgical removal of the catheter with or without excision of the pseudocyst wall and implantation of a new catheter, 11 or cyst excision and shunt relocation 12,13 are treatment options for this pseudocyst. Shunt relocation includes VA shunt, VPL shunt, and LP shunt 14 …”

Section: Discussionmentioning

confidence: 99%

“…The treatment options for such pseudocysts include surgical removal of the catheter with or without excision of the pseudocyst wall and placement of a new catheter 11 or cyst excision and shunt relocation 12,13 . Shunt relocation includes ventriculoatrial (VA) shunt, ventriculopleural (VPL) shunt, and lumboperitoneal (LP) shunt 14 …”

Section: Introductionmentioning

confidence: 99%

“…12,13 Shunt relocation includes ventriculoatrial (VA) shunt, ventriculopleural (VPL) shunt, and lumboperitoneal (LP) shunt. 14 A VPL shunt is a reasonable alternative for hydrocephalus when the traditional VP shunt fails. [15][16][17] We present a case of a two-and-a-half-year-old male child with complicated VP shunt placement for congenital hydrocephalus that developed an abdominal pseudocyst and had to undergo VPL shunt placement for further management.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Abdominal pseudocyst complicating ventriculoperitoneal shunt: A rare indication for ventriculopleural shunt conversion

Shrestha,

Gautam,

Shrestha

2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageAbdominal pseudocyst is a rare complication of ventriculoperitoneal (VP) shunt placement. Ventriculopleural shunt (VPL) can be an effective treatment option for the recurrent complications of VP shunt failure.AbstractAbdominal pseudocyst (APC) is a rare complication of ventriculoperitoneal (VP) shunt placement for the treatment of congenital hydrocephalus. This case report presents a two‐and‐a‐half‐year‐old male child who underwent VP shunt placement for aqueductal stenosis‐related hydrocephalus. The patient subsequently developed recurrent shunt failure and an APC, which was managed initially by surgical excision of the cyst and repositioning of the catheter. However, shunt failure recurred. The patient underwent ventriculopleural (VPL) shunt conversion as a more viable option for recurrent blockage. Postoperatively, the patient developed respiratory distress with massive pleural effusion, which was treated with chest tube insertion. This case highlights the complexity of managing congenital hydrocephalus and its rare complication, APC. Prompt recognition and appropriate management of APC can lead to improved outcomes and minimize the need for invasive procedures. VPL shunt conversion can be considered an alternative treatment option when other treatments have failed. Further research is needed to establish guidelines for the management of APC and determine the long‐term effectiveness of VPL shunting.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Abdominal pseudocyst complicating ventriculoperitoneal shunt: A rare indication for ventriculopleural shunt conversion

Shrestha,

Gautam,

Shrestha

2023

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Are ventriculopleural shunts the second option for treating hydrocephalus? A meta-analysis of 543 patients

Oliveira,

Porto,

Andreão

et al. 2024

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Targeting modulation of the choroid plexus blood-CSF barrier and CSF hypersecretion via lipid nanoparticle-mediated co-delivery siRNA and resveratrol

Gao,

Wang,

Xia

et al. 2024

Preprint

View full text Add to dashboard Cite

Hydrocephalus is one of the most common neurological disorders, but pharmacotherapy options are currently lacking due to the complex pathogenesis. The blood-CSF barrier (B-CSFB), consisting of choroid plexus (ChP) epithelial cells, is a crucial gate for the entry of peripheral immune cells and its dysfunction emerges as a new contributor to hydrocephalus pathology. Meanwhile, SPAK-mediated CSF hypersecretion in ChP epithelial cells plays an important role in the pathogenesis of hydrocephalus. Here, we fabricated a transferrin receptor-targeted nano-drug (siR/RSV@TNP) that can intelligently navigate to the blood-CSF barrier and prepared for combined delivery of resveratrol (RSV) and SPAK siRNA (siSPAK)for synergetic hydrocephalus therapy. As expected, siR/RSV@TNP fulfilled its function of knocking down SPAK expression, relieving inflammation and oxidative stress, retrieving blood-CSF barrier integrity, and ultimately preventing ventriculomegaly and hydrocephalus. The current study demonstrates proof of concept that targeting the choroid plexus blood-CSF barrier and cerebrospinal fluid hypersecretion offers a promising and innovative approach for alleviating hydrocephalus.

show abstract

Ventriculopleural shunt outcomes for pediatric hydrocephalus: a single-institution experience

Cited by 3 publications

References 34 publications

Abdominal pseudocyst complicating ventriculoperitoneal shunt: A rare indication for ventriculopleural shunt conversion

Abdominal pseudocyst complicating ventriculoperitoneal shunt: A rare indication for ventriculopleural shunt conversion

Are ventriculopleural shunts the second option for treating hydrocephalus? A meta-analysis of 543 patients

Targeting modulation of the choroid plexus blood-CSF barrier and CSF hypersecretion via lipid nanoparticle-mediated co-delivery siRNA and resveratrol

Contact Info

Product

Resources

About